Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

NCT07681297 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor Cancer
Triple-Negative Breast Cancer (TNBC)
CNS Disease
Breast Cancer

Interventions

DRUG: Tislelizumab + Bevacizumab + Capecitabine

Sponsor

National University Hospital, Singapore